Neovia Oncology Inc.

Seattle
Washington
United States

Tel: 425-298-4099

Email: information@neoviaoncology.com

Show jobs for this employer

About Neovia Oncology Inc.

Neovia develops oncology drugs that enhance immunotherapy response to overcome drug resistance and has begun a Phase 1 clinical trial designed to evaluate our lead multi-inhibitor, (NEV-801), that has the potential to treat patients with advanced drug-resistant cancers.
Normally, immunotherapy rarely controls clinically significant tumors that fail to express target antigens, and thereby fail to elicit an effective immune response. However, there is mounting evidence that tumor antigen production can be deliberately stimulated to promote immune recognition and response.
LEADERSHIP:
Founder and CEO: Trevor Blake
Co-Founder: Raymond Su
COO: Gerald Su
CLINICAL TRIAL:
Please click here for clinical trial information.

2 articles about Neovia Oncology Inc.